Three reclassified reports were issued including a deletion of exons 1–15 of CHEK2 in a male participant diagnosed with prostate cancer at age 46 with a strong family history of prostate cancer17, a male participant with a deletion of both BRCA2 and RB1, and a male participant discovered to be homozygous for Factor V Leiden. This evidence concerns the gene CHEK2 and prostate cancer.